Certainly, the news inspired a ‘draught of positive responses’ (monstersandcritics.com, 9 June), not least in applause of the speed of the announcement: ‘It is gratifying to see NICE respond so quickly’ (Professor Sikora, Daily Mail, 9 June).
Many welcomed NICE’s action, particularly given Herceptin’s history of personal campaigns, litigation and exposure of UK healthcare rationing. ‘A year of uncertainty and post-code lottery is at last coming to an end’ (Breakthrough Breast Cancer, 4ni.co.uk, 9 June).
Cautionary tales were never far away, however. Kate Law, of Cancer Research UK, stated: ‘We must remember Herceptin is only suitable in about one in five cases of breast cancer. So it’s essential not to create a climate where Herceptin is seen as a miracle cure’ (politics.co.uk, 9 June).
There were also financial concerns. With the NHS in debt, questions of funding were inevitably raised: ‘Herceptin for all to cost £91m a year’ (The Times, 9 June).
Analysis conducted by Echo Research from data supplied to PRWeek from NewsNow.